ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2003

Cumulative Incidence of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis in Lung Cancer Patients with and Without Hip Osteoarthritis and Impacts on Survival

Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 2174

Current Treatment of Macrophage Activation Syndrome Worldwide: The METAPHOR Project, a PReS/PRINTO Real-life International Survey

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1798

CXCL6 Synthesized by Proximal Tubule Cells May Promote Fibrosis in Lupus Nephritis

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2118

Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2309

Damage Accrual Predicts the Development of Lymphoma in Primary Sjogren’s Syndrome

Sjögren's Syndrome – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2430

Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial

SLE – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1783

Deciphering the Roles of Mitochondrial-Related Genes and Ferroptosis in Systemic Lupus Erythematosus: Integrated Analysis for Diagnostic Biomarker Identification and Therapeutic Insights

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2306

Deconstruction and Reconstruction of Sjögren’s Disease: AMP®-AIM Partnership

Sjögren's Syndrome – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2107

Deep Immunophenotyping of Knee Osteoarthritis Patients Reveals Alterations in T Cell, Treg, and Monocyte Subpopulations

Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2307

Deep Spatial Profiling Unveils Dominant Double Negative B Cells in Severe Forms of Sjögren’s Syndrome

Sjögren's Syndrome – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2282

Defining a Personalized Treatment Approach to Rheumatoid Arthritis: Using Genetic Markers of TNFi Response

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2055

Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2393

Demographic Differences in Trends of Systemic Lupus Erythematosus In-hospital Patient Outcomes

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2256

Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2499

Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].